News

Intraoperative RT Valuable Alternative to EBRT for Locally Advanced Rectal Cancer

01/17/2020

Findings from a retrospective study posit intraoperative RT as a valuable treatment option for patients with locally advanced rectal cancer unable to receive EBRT.

Findings from a retrospective...

01/17/2020

Oncology

News

No Long-Term Improvement With Lateral Lymph Node Dissection for Rectal Cancer

01/14/2020

Lateral lymph node dissection did not improve long-term outcomes in patients with rectal cancer, according to findings from a meta-analysis.

Lateral lymph node dissection...

01/14/2020

Oncology

News

No Benefit to Continuing Full Induction Regimen Alone in Metastatic CRC

01/06/2020

Investigators assert that there is no benefit to continuing a full induction regimen alone until progression in patients with metastatic CRC.

Investigators assert that there...

01/06/2020

Oncology

News

Adding Aflibercept to Modified FOLFOX6 Improves Response in High-Risk Rectal Cancer

12/17/2019

Results from a phase 2 study suggest that adding aflibercept to mFOLFOX6 induction chemo helps increase pCR rates in high-risk rectal cancer.

Results from a phase 2 study...

12/17/2019

Oncology

News

CT Scans May Predict Benefit of Preoperative Therapy for Sigmoid Colon Cancer

12/12/2019

Study results suggest that identification of tumor deposits and extramural venous invasion via CT scans may predict whether patients with sigmoid colon cancer will benefit from preoperative therapy.

Study results suggest that...

12/12/2019

Oncology

News

Researchers Unveil Method to Identify Patients With CRC and NTRK Gene Fusions

12/06/2019

Researchers have unveiled an effective method for identifying the majority of patients with CRC who have NTRK gene fusions.

Researchers have unveiled an...

12/06/2019

Oncology

News

Differentiating Tumor Tissue From Fibrosis in Surgery for CRC a Possibility

12/06/2019

Investigators suggest that it may be feasible to differentiate pure fibrosis from pure tumor during surgery in patients with CRC.

Investigators suggest that it...

12/06/2019

Oncology

News

Triplet Regimen Significantly Improves OS in BRAF V600E-Mutated Metastatic CRC

10/18/2019

Encorafenib, combined with cetuximab and binimetinib resulted in significantly longer OS and a higher response rate compared with standard therapy in patients with metastatic CRC harboring the BRAF v600E mutation.

Encorafenib, combined with...

10/18/2019

Oncology

News

Incidence of Microsatellite Instability in Metastatic CRC High, Tied to Worse Survival

06/13/2019

Results from a recent study of patients with metastatic CRC suggest that immunotherapy should be considered as first-line treatment in those with MSI-H tumors.

Results from a recent study of...

06/13/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology